Botulinum injection is useless on fibrotic neuropathic bladders
Objective Studies on the use of intradetrusor botulinum toxin A injection for children with neuropathic bladders are insufficient and the results are controversial. The aim of the present study was to evaluate the effect of intradetrusor botulinum toxin A injection for children with neuropathic blad...
Saved in:
Published in | Journal of pediatric urology Vol. 11; no. 1; pp. 27.e1 - 27.e4 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.02.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objective Studies on the use of intradetrusor botulinum toxin A injection for children with neuropathic bladders are insufficient and the results are controversial. The aim of the present study was to evaluate the effect of intradetrusor botulinum toxin A injection for children with neuropathic bladders that are resistant to anticholinergic treatment, and to reveal any criteria indicating treatment success. Patients/methods Hospital records were reviewed of 16 children with neuropathic bladders due to myelomeningocele, and who had botulinum toxin A injections between 2007 and 2010. Botulinum toxin A (10 units/kg) was injected endoscopically into various sites of the detrusor, except the trigone. The success was defined as complete dryness between clean intermittent catheterizations. Urodynamic studies before and after the application were evaluated and parameters, including bladder capacity (measured/expected) and compliance, were also analyzed. Reviewing the results, patients were then classified into two groups: as having fibrotic bladders (noncompliant, acontractile bladders with high pressures) or overactive bladders. Urodynamic findings and therapy success were then compared between the groups. Results A total of 19 injections, including repeat injections in three patients, were performed. Results of the 16 initial injections were evaluated. Nine patients had detrusor overactivity, and five out of nine (56%) applications in this group resulted in complete dryness between clean intermittent catheterizations. In bladders with typical detrusor overactivity, there was a significant increase in both the capacity (from 0.53 to 0.74) and compliance (from 4.7 to 8.6 ml/cm H2 O). Looking at the seven patients that displayed fibrotic bladders with very low compliance and no contraction at all, none of them presented with notable clinical improvement from injections. Comparing the urodynamic findings, there was no significant difference in compliance (3.1 ml/cm H2 O before and 3.5 ml/cm H2 O after) and bladder capacity (0.58 before and 0.52 after the treatment) in the fibrotic bladders. Discussion Despite its worldwide usage and FDA approval, studies on the effectiveness of botulinumtoxin A on neuropathic bladders in children are controversial. There are now numerous studies attesting to the good results of BoNTA in neuropathic detrusor overactivity; however, only scarce reports comment on the specific features of the disease process among patients and reasons for failure in some. In our study, reviewing the urodynamic findings carefully, it was observed that the patients who did not respond to injections were the ones with no contractions, despite high pressures and low compliance. Therefore, describing the indications of BoNTA as neuropathic detrusor overactivity and urinary incontinence despite anticholinergic medications may lead to mistreatment of patients in the decompensated phase of a hyper-reflexive detrusor. Pretreatment urodynamic evaluation might be a good indicator, without biopsies, of estimating the degree of fibrosis and the patients who will benefit from the injection. Conclusion Botulinum toxin A injection in the neuropathic bladder of myelomeningocele patients was found to be ineffective if the detrusor was fibrotic, of low compliance and had lost contractility. Urodynamic findings should be carefully analyzed in order to select appropriate patients that may benefit from Botulinum injection. |
---|---|
AbstractList | OBJECTIVEStudies on the use of intradetrusor botulinum toxin A injection for children with neuropathic bladders are insufficient and the results are controversial. The aim of the present study was to evaluate the effect of intradetrusor botulinum toxin A injection for children with neuropathic bladders that are resistant to anticholinergic treatment, and to reveal any criteria indicating treatment success.PATIENTS/METHODSHospital records were reviewed of 16 children with neuropathic bladders due to myelomeningocele, and who had botulinum toxin A injections between 2007 and 2010. Botulinum toxin A (10 units/kg) was injected endoscopically into various sites of the detrusor, except the trigone. The success was defined as complete dryness between clean intermittent catheterizations. Urodynamic studies before and after the application were evaluated and parameters, including bladder capacity (measured/expected) and compliance, were also analyzed. Reviewing the results, patients were then classified into two groups: as having fibrotic bladders (noncompliant, acontractile bladders with high pressures) or overactive bladders. Urodynamic findings and therapy success were then compared between the groups.RESULTSA total of 19 injections, including repeat injections in three patients, were performed. Results of the 16 initial injections were evaluated. Nine patients had detrusor overactivity, and five out of nine (56%) applications in this group resulted in complete dryness between clean intermittent catheterizations. In bladders with typical detrusor overactivity, there was a significant increase in both the capacity (from 0.53 to 0.74) and compliance (from 4.7 to 8.6 ml/cm H2O). Looking at the seven patients that displayed fibrotic bladders with very low compliance and no contraction at all, none of them presented with notable clinical improvement from injections. Comparing the urodynamic findings, there was no significant difference in compliance (3.1 ml/cm H2O before and 3.5 ml/cm H2O after) and bladder capacity (0.58 before and 0.52 after the treatment) in the fibrotic bladders.DISCUSSIONDespite its worldwide usage and FDA approval, studies on the effectiveness of botulinumtoxin A on neuropathic bladders in children are controversial. There are now numerous studies attesting to the good results of BoNTA in neuropathic detrusor overactivity; however, only scarce reports comment on the specific features of the disease process among patients and reasons for failure in some. In our study, reviewing the urodynamic findings carefully, it was observed that the patients who did not respond to injections were the ones with no contractions, despite high pressures and low compliance. Therefore, describing the indications of BoNTA as neuropathic detrusor overactivity and urinary incontinence despite anticholinergic medications may lead to mistreatment of patients in the decompensated phase of a hyper-reflexive detrusor. Pretreatment urodynamic evaluation might be a good indicator, without biopsies, of estimating the degree of fibrosis and the patients who will benefit from the injection.CONCLUSIONBotulinum toxin A injection in the neuropathic bladder of myelomeningocele patients was found to be ineffective if the detrusor was fibrotic, of low compliance and had lost contractility. Urodynamic findings should be carefully analyzed in order to select appropriate patients that may benefit from Botulinum injection. Objective Studies on the use of intradetrusor botulinum toxin A injection for children with neuropathic bladders are insufficient and the results are controversial. The aim of the present study was to evaluate the effect of intradetrusor botulinum toxin A injection for children with neuropathic bladders that are resistant to anticholinergic treatment, and to reveal any criteria indicating treatment success. Patients/methods Hospital records were reviewed of 16 children with neuropathic bladders due to myelomeningocele, and who had botulinum toxin A injections between 2007 and 2010. Botulinum toxin A (10 units/kg) was injected endoscopically into various sites of the detrusor, except the trigone. The success was defined as complete dryness between clean intermittent catheterizations. Urodynamic studies before and after the application were evaluated and parameters, including bladder capacity (measured/expected) and compliance, were also analyzed. Reviewing the results, patients were then classified into two groups: as having fibrotic bladders (noncompliant, acontractile bladders with high pressures) or overactive bladders. Urodynamic findings and therapy success were then compared between the groups. Results A total of 19 injections, including repeat injections in three patients, were performed. Results of the 16 initial injections were evaluated. Nine patients had detrusor overactivity, and five out of nine (56%) applications in this group resulted in complete dryness between clean intermittent catheterizations. In bladders with typical detrusor overactivity, there was a significant increase in both the capacity (from 0.53 to 0.74) and compliance (from 4.7 to 8.6 ml/cm H2 O). Looking at the seven patients that displayed fibrotic bladders with very low compliance and no contraction at all, none of them presented with notable clinical improvement from injections. Comparing the urodynamic findings, there was no significant difference in compliance (3.1 ml/cm H2 O before and 3.5 ml/cm H2 O after) and bladder capacity (0.58 before and 0.52 after the treatment) in the fibrotic bladders. Discussion Despite its worldwide usage and FDA approval, studies on the effectiveness of botulinumtoxin A on neuropathic bladders in children are controversial. There are now numerous studies attesting to the good results of BoNTA in neuropathic detrusor overactivity; however, only scarce reports comment on the specific features of the disease process among patients and reasons for failure in some. In our study, reviewing the urodynamic findings carefully, it was observed that the patients who did not respond to injections were the ones with no contractions, despite high pressures and low compliance. Therefore, describing the indications of BoNTA as neuropathic detrusor overactivity and urinary incontinence despite anticholinergic medications may lead to mistreatment of patients in the decompensated phase of a hyper-reflexive detrusor. Pretreatment urodynamic evaluation might be a good indicator, without biopsies, of estimating the degree of fibrosis and the patients who will benefit from the injection. Conclusion Botulinum toxin A injection in the neuropathic bladder of myelomeningocele patients was found to be ineffective if the detrusor was fibrotic, of low compliance and had lost contractility. Urodynamic findings should be carefully analyzed in order to select appropriate patients that may benefit from Botulinum injection. Studies on the use of intradetrusor botulinum toxin A injection for children with neuropathic bladders are insufficient and the results are controversial. The aim of the present study was to evaluate the effect of intradetrusor botulinum toxin A injection for children with neuropathic bladders that are resistant to anticholinergic treatment, and to reveal any criteria indicating treatment success. Hospital records were reviewed of 16 children with neuropathic bladders due to myelomeningocele, and who had botulinum toxin A injections between 2007 and 2010. Botulinum toxin A (10 units/kg) was injected endoscopically into various sites of the detrusor, except the trigone. The success was defined as complete dryness between clean intermittent catheterizations. Urodynamic studies before and after the application were evaluated and parameters, including bladder capacity (measured/expected) and compliance, were also analyzed. Reviewing the results, patients were then classified into two groups: as having fibrotic bladders (noncompliant, acontractile bladders with high pressures) or overactive bladders. Urodynamic findings and therapy success were then compared between the groups. A total of 19 injections, including repeat injections in three patients, were performed. Results of the 16 initial injections were evaluated. Nine patients had detrusor overactivity, and five out of nine (56%) applications in this group resulted in complete dryness between clean intermittent catheterizations. In bladders with typical detrusor overactivity, there was a significant increase in both the capacity (from 0.53 to 0.74) and compliance (from 4.7 to 8.6 ml/cm H2O). Looking at the seven patients that displayed fibrotic bladders with very low compliance and no contraction at all, none of them presented with notable clinical improvement from injections. Comparing the urodynamic findings, there was no significant difference in compliance (3.1 ml/cm H2O before and 3.5 ml/cm H2O after) and bladder capacity (0.58 before and 0.52 after the treatment) in the fibrotic bladders. Despite its worldwide usage and FDA approval, studies on the effectiveness of botulinumtoxin A on neuropathic bladders in children are controversial. There are now numerous studies attesting to the good results of BoNTA in neuropathic detrusor overactivity; however, only scarce reports comment on the specific features of the disease process among patients and reasons for failure in some. In our study, reviewing the urodynamic findings carefully, it was observed that the patients who did not respond to injections were the ones with no contractions, despite high pressures and low compliance. Therefore, describing the indications of BoNTA as neuropathic detrusor overactivity and urinary incontinence despite anticholinergic medications may lead to mistreatment of patients in the decompensated phase of a hyper-reflexive detrusor. Pretreatment urodynamic evaluation might be a good indicator, without biopsies, of estimating the degree of fibrosis and the patients who will benefit from the injection. Botulinum toxin A injection in the neuropathic bladder of myelomeningocele patients was found to be ineffective if the detrusor was fibrotic, of low compliance and had lost contractility. Urodynamic findings should be carefully analyzed in order to select appropriate patients that may benefit from Botulinum injection. Studies on the use of intradetrusor botulinum toxin A injection for children with neuropathic bladders are insufficient and the results are controversial. The aim of the present study was to evaluate the effect of intradetrusor botulinum toxin A injection for children with neuropathic bladders that are resistant to anticholinergic treatment, and to reveal any criteria indicating treatment success. Hospital records were reviewed of 16 children with neuropathic bladders due to myelomeningocele, and who had botulinum toxin A injections between 2007 and 2010. Botulinum toxin A (10 units/kg) was injected endoscopically into various sites of the detrusor, except the trigone. The success was defined as complete dryness between clean intermittent catheterizations. Urodynamic studies before and after the application were evaluated and parameters, including bladder capacity (measured/expected) and compliance, were also analyzed. Reviewing the results, patients were then classified into two groups: as having fibrotic bladders (noncompliant, acontractile bladders with high pressures) or overactive bladders. Urodynamic findings and therapy success were then compared between the groups. A total of 19 injections, including repeat injections in three patients, were performed. Results of the 16 initial injections were evaluated. Nine patients had detrusor overactivity, and five out of nine (56%) applications in this group resulted in complete dryness between clean intermittent catheterizations. In bladders with typical detrusor overactivity, there was a significant increase in both the capacity (from 0.53 to 0.74) and compliance (from 4.7 to 8.6 ml/cm H2O). Looking at the seven patients that displayed fibrotic bladders with very low compliance and no contraction at all, none of them presented with notable clinical improvement from injections. Comparing the urodynamic findings, there was no significant difference in compliance (3.1 ml/cm H2O before and 3.5 ml/cm H2O after) and bladder capacity (0.58 before and 0.52 after the treatment) in the fibrotic bladders. Despite its worldwide usage and FDA approval, studies on the effectiveness of botulinumtoxin A on neuropathic bladders in children are controversial. There are now numerous studies attesting to the good results of BoNTA in neuropathic detrusor overactivity; however, only scarce reports comment on the specific features of the disease process among patients and reasons for failure in some. In our study, reviewing the urodynamic findings carefully, it was observed that the patients who did not respond to injections were the ones with no contractions, despite high pressures and low compliance. Therefore, describing the indications of BoNTA as neuropathic detrusor overactivity and urinary incontinence despite anticholinergic medications may lead to mistreatment of patients in the decompensated phase of a hyper-reflexive detrusor. Pretreatment urodynamic evaluation might be a good indicator, without biopsies, of estimating the degree of fibrosis and the patients who will benefit from the injection. Botulinum toxin A injection in the neuropathic bladder of myelomeningocele patients was found to be ineffective if the detrusor was fibrotic, of low compliance and had lost contractility. Urodynamic findings should be carefully analyzed in order to select appropriate patients that may benefit from Botulinum injection. |
Author | Tiryaki, S Akyildiz, C Avanoglu, A Parlar, Y Yagmur, I Ozel, K Ulman, I |
Author_xml | – sequence: 1 fullname: Tiryaki, S – sequence: 2 fullname: Yagmur, I – sequence: 3 fullname: Parlar, Y – sequence: 4 fullname: Ozel, K – sequence: 5 fullname: Akyildiz, C – sequence: 6 fullname: Avanoglu, A – sequence: 7 fullname: Ulman, I |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25448589$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU1P3DAQhi20iGUp_6BCOfaS4K_440JVVm1BQuoBerYSeyKcZu3FTirx7-vVQg-99DQz1jvzjp_ZoFWIARD6SHBDMBHXYzPulxSnhmLCG6wajPUJOidKsporrVYl51LWLWFkjTY5jxgziak-Q2vacq5apc_R59s4L5MPy67yYQQ7-xgqn6slwwQ5V6UafJ_i7G0VoPjtu_m55P3UOQcpf0CnQzdluHyLF-jnt69P27v64cf3--2Xh9pyJedauMFaxSlVLWcDUNa1LXaKC1fedC-F05JIbS2RFpwWusOcUcUHJaG3bmAX6NNx7j7FlwXybHY-W5imLkBcsiFCSC0E47JI-VFqU8w5wWD2ye-69GoINgd0ZjRHdOaAzmBlCrrSdvXmsPQ7cH-b3lkVwc1RAOWfvz0kk62HUPb1qYAzLvr_Ofw7wBby3nbTL3iFPMYlhcLQEJOpwebxcL7D9QjHmAqp2B-KfZh1 |
CitedBy_id | crossref_primary_10_1016_j_urpr_2018_06_002 crossref_primary_10_3390_biology10090863 crossref_primary_10_1002_nau_23391 crossref_primary_10_1002_nau_24962 crossref_primary_10_1016_j_jpurol_2021_12_002 crossref_primary_10_1007_s00345_015_1666_5 crossref_primary_10_1016_j_urology_2021_09_045 crossref_primary_10_1590_s1677_5538_ibju_2020_0989 crossref_primary_10_1002_nau_23296 crossref_primary_10_4103_iju_IJU_358_16 crossref_primary_10_1007_s40272_017_0249_x crossref_primary_10_1007_s40746_018_0115_2 crossref_primary_10_3390_ijms24119501 crossref_primary_10_1002_nau_24248 crossref_primary_10_1016_j_ucl_2018_06_005 crossref_primary_10_1080_0886022X_2023_2194440 crossref_primary_10_1016_j_ucl_2017_04_012 crossref_primary_10_1097_MOU_0000000000000352 crossref_primary_10_1002_nau_23025 crossref_primary_10_1002_nau_23725 crossref_primary_10_1080_14737175_2023_2246661 crossref_primary_10_1007_s00345_020_03203_1 crossref_primary_10_1007_s11884_019_00516_9 crossref_primary_10_3389_fped_2024_1407009 crossref_primary_10_1016_j_jpurol_2016_01_002 crossref_primary_10_1016_j_urology_2018_02_033 crossref_primary_10_1016_j_urology_2022_04_020 crossref_primary_10_36290_uro_2019_040 |
Cites_doi | 10.1007/s00467-007-0691-z 10.1111/j.1464-410X.1985.tb05860.x 10.4103/0970-1591.109975 10.1016/S0022-5347(06)00305-3 10.1111/j.1464-410X.2007.06575.x 10.1016/j.jpurol.2013.10.011 10.1016/j.eururo.2006.01.025 10.1016/S0022-5347(05)67730-0 10.1016/j.eururo.2011.07.001 10.1179/2045772313Y.0000000116 10.1111/j.1464-410X.2010.09445.x 10.1097/01.ju.0000108892.35041.2d |
ContentType | Journal Article |
Copyright | Journal of Pediatric Urology Company 2014 Journal of Pediatric Urology Company Copyright © 2014 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved. |
Copyright_xml | – notice: Journal of Pediatric Urology Company – notice: 2014 Journal of Pediatric Urology Company – notice: Copyright © 2014 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1016/j.jpurol.2014.08.009 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1873-4898 |
EndPage | 27.e4 |
ExternalDocumentID | 10_1016_j_jpurol_2014_08_009 25448589 S1477513114002678 1_s2_0_S1477513114002678 |
Genre | Journal Article |
GroupedDBID | --- --K --M -RU .1- .FO .~1 0R~ 1B1 1P~ 1~. 1~5 4.4 457 4G. 53G 5GY 5VS 7-5 71M 8P~ AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAXKI AAXUO ABBQC ABJNI ABMAC ABMZM ABPPZ ABXDB ACDAQ ACGFS ACRLP ADBBV ADEZE ADMUD AEBSH AEKER AENEX AEVXI AFCTW AFJKZ AFKWA AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR BKOJK BLXMC BNPGV CS3 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W KOM M41 MO0 N9A O-L O9- OAUVE OK. OW. OZT P-8 P-9 P2P PC. Q38 RIG ROL RPZ SDF SDG SEL SES SEW SPCBC SSH SSZ T5K Z5R ~G- AAIAV ABLVK ABYKQ AJBFU EFLBG LCYCR CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c487t-6dfcc84228543fe23a550d846d4229b76d97179cc17ced969a043284f87ebcdf3 |
IEDL.DBID | AIKHN |
ISSN | 1477-5131 |
IngestDate | Fri Aug 16 01:39:13 EDT 2024 Thu Sep 26 19:19:41 EDT 2024 Sat Sep 28 08:06:42 EDT 2024 Fri Feb 23 02:29:51 EST 2024 Tue Oct 15 22:56:21 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Botulinum toxin A Urodynamic study Neuropathic bladder |
Language | English |
License | Copyright © 2014 Journal of Pediatric Urology Company. Published by Elsevier Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c487t-6dfcc84228543fe23a550d846d4229b76d97179cc17ced969a043284f87ebcdf3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 25448589 |
PQID | 1667966347 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_1667966347 crossref_primary_10_1016_j_jpurol_2014_08_009 pubmed_primary_25448589 elsevier_sciencedirect_doi_10_1016_j_jpurol_2014_08_009 elsevier_clinicalkeyesjournals_1_s2_0_S1477513114002678 |
PublicationCentury | 2000 |
PublicationDate | 2015-02-01 |
PublicationDateYYYYMMDD | 2015-02-01 |
PublicationDate_xml | – month: 02 year: 2015 text: 2015-02-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of pediatric urology |
PublicationTitleAlternate | J Pediatr Urol |
PublicationYear | 2015 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | Orasanu, Mahajan (bib1) 2013; 29 Neveus, von Gontard, Hoebeke, Hjalmas, Bauer, Bower (bib5) 2006; 176 Gilpin, Gosling, Barnard (bib12) 1985; 57 Metcalfe, Wang, Jiao, Huang, Hori, Moore (bib10) 2010; 106 Figueroa, Romao, Salle, Koyle, Braga, Baglia (bib14) 2014; 10 Mangera, Andersson, Apostolidis, Chapple, Dasgupta, Giannantoni (bib2) 2011; 60 Riccabona, Koen, Schindler, Goedele, Pycha, Lusuardi (bib4) 2004; 171 Linsenmeyer (bib6) 2013; 36 Dmochowski, Sand (bib7) 2007; 99 Verpoorten, Buyse (bib11) 2008; 23 Comperat, Reitz, Delcourt, Capron, Denys, Chartier-Kastler (bib8) 2006; 50 Kask, Rintala, Taskinen (bib3) 2013; xx Macarak, Howard (bib13) 1997; 184 Weld, Graney, Dmochowski (bib9) 2000; 163 Riccabona (10.1016/j.jpurol.2014.08.009_bib4) 2004; 171 Comperat (10.1016/j.jpurol.2014.08.009_bib8) 2006; 50 Verpoorten (10.1016/j.jpurol.2014.08.009_bib11) 2008; 23 Figueroa (10.1016/j.jpurol.2014.08.009_bib14) 2014; 10 Weld (10.1016/j.jpurol.2014.08.009_bib9) 2000; 163 Orasanu (10.1016/j.jpurol.2014.08.009_bib1) 2013; 29 Mangera (10.1016/j.jpurol.2014.08.009_bib2) 2011; 60 Dmochowski (10.1016/j.jpurol.2014.08.009_bib7) 2007; 99 Neveus (10.1016/j.jpurol.2014.08.009_bib5) 2006; 176 Linsenmeyer (10.1016/j.jpurol.2014.08.009_bib6) 2013; 36 Gilpin (10.1016/j.jpurol.2014.08.009_bib12) 1985; 57 Macarak (10.1016/j.jpurol.2014.08.009_bib13) 1997; 184 Metcalfe (10.1016/j.jpurol.2014.08.009_bib10) 2010; 106 Kask (10.1016/j.jpurol.2014.08.009_bib3) 2013; xx |
References_xml | – volume: 29 start-page: 2 year: 2013 end-page: 11 ident: bib1 article-title: The use of botulinum toxin for the treatment of overactive bladder syndrome publication-title: Indian J Urol contributor: fullname: Mahajan – volume: 60 start-page: 784 year: 2011 end-page: 795 ident: bib2 article-title: Contemporary management of lower urinary Tract disease with botulinum toxin a: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA) publication-title: Eur Urol contributor: fullname: Giannantoni – volume: 176 start-page: 314 year: 2006 end-page: 324 ident: bib5 article-title: The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardization Committee of the International Children's Continence Society publication-title: J Urol contributor: fullname: Bower – volume: 36 start-page: 402 year: 2013 end-page: 419 ident: bib6 article-title: Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review publication-title: J Spinal Cord Med contributor: fullname: Linsenmeyer – volume: 106 start-page: 1686 year: 2010 end-page: 1694 ident: bib10 article-title: Bladder outlet obstruction: progression from inflammation to fibrosis publication-title: BJU Int contributor: fullname: Moore – volume: xx start-page: 1e4 year: 2013 ident: bib3 article-title: Effect of onabotulinumtoxinA treatment on symptoms and urodynamic findings in pediatric neurogenic bladder publication-title: J Pediatr Urol contributor: fullname: Taskinen – volume: 184 start-page: 25 year: 1997 end-page: 33 ident: bib13 article-title: The collagens and their urologic significance publication-title: Scand J Urol Nephrol contributor: fullname: Howard – volume: 10 start-page: 368 year: 2014 end-page: 373 ident: bib14 article-title: Single-center experience with botulinum toxin endoscopic detrusor injection for the treatment of congenital neuropathic bladder in children: effect of dose adjustment, multiple injections, and avoidance of reconstructive procedures publication-title: J Pediatr Urol contributor: fullname: Baglia – volume: 171 start-page: 845 year: 2004 end-page: 848 ident: bib4 article-title: Botulinum-A injection into the detrusor: a safe alternative in the treatment of children with meningomyelocele with detrusor hyperreflexia publication-title: J Urol contributor: fullname: Lusuardi – volume: 23 start-page: 717 year: 2008 end-page: 725 ident: bib11 article-title: The neurogenic bladder: medical treatment publication-title: Pediatr Nephrol contributor: fullname: Buyse – volume: 99 start-page: 247 year: 2007 end-page: 262 ident: bib7 article-title: Botulinum toxin A in the overactive bladder: current status and future directions publication-title: BJU Int contributor: fullname: Sand – volume: 57 start-page: 525 year: 1985 end-page: 529 ident: bib12 article-title: Morphological and morphometric studies of the human obstructed, trabeculated urinary bladder publication-title: Brit J Urol contributor: fullname: Barnard – volume: 163 start-page: 1228 year: 2000 end-page: 1233 ident: bib9 article-title: Differences in bladder compliance with time and associations of bladder management with compliance in spinal cord injured patients publication-title: J Urol contributor: fullname: Dmochowski – volume: 50 start-page: 1058 year: 2006 end-page: 1064 ident: bib8 article-title: Histologic features in the urinary bladder wall affected from neurogenic overactivity—a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A publication-title: Eur Urol contributor: fullname: Chartier-Kastler – volume: xx start-page: 1e4 year: 2013 ident: 10.1016/j.jpurol.2014.08.009_bib3 article-title: Effect of onabotulinumtoxinA treatment on symptoms and urodynamic findings in pediatric neurogenic bladder publication-title: J Pediatr Urol contributor: fullname: Kask – volume: 23 start-page: 717 year: 2008 ident: 10.1016/j.jpurol.2014.08.009_bib11 article-title: The neurogenic bladder: medical treatment publication-title: Pediatr Nephrol doi: 10.1007/s00467-007-0691-z contributor: fullname: Verpoorten – volume: 57 start-page: 525 year: 1985 ident: 10.1016/j.jpurol.2014.08.009_bib12 article-title: Morphological and morphometric studies of the human obstructed, trabeculated urinary bladder publication-title: Brit J Urol doi: 10.1111/j.1464-410X.1985.tb05860.x contributor: fullname: Gilpin – volume: 184 start-page: 25 issue: Suppl. year: 1997 ident: 10.1016/j.jpurol.2014.08.009_bib13 article-title: The collagens and their urologic significance publication-title: Scand J Urol Nephrol contributor: fullname: Macarak – volume: 29 start-page: 2 issue: 1 year: 2013 ident: 10.1016/j.jpurol.2014.08.009_bib1 article-title: The use of botulinum toxin for the treatment of overactive bladder syndrome publication-title: Indian J Urol doi: 10.4103/0970-1591.109975 contributor: fullname: Orasanu – volume: 176 start-page: 314 year: 2006 ident: 10.1016/j.jpurol.2014.08.009_bib5 article-title: The standardization of terminology of lower urinary tract function in children and adolescents: report from the Standardization Committee of the International Children's Continence Society publication-title: J Urol doi: 10.1016/S0022-5347(06)00305-3 contributor: fullname: Neveus – volume: 99 start-page: 247 year: 2007 ident: 10.1016/j.jpurol.2014.08.009_bib7 article-title: Botulinum toxin A in the overactive bladder: current status and future directions publication-title: BJU Int doi: 10.1111/j.1464-410X.2007.06575.x contributor: fullname: Dmochowski – volume: 10 start-page: 368 year: 2014 ident: 10.1016/j.jpurol.2014.08.009_bib14 article-title: Single-center experience with botulinum toxin endoscopic detrusor injection for the treatment of congenital neuropathic bladder in children: effect of dose adjustment, multiple injections, and avoidance of reconstructive procedures publication-title: J Pediatr Urol doi: 10.1016/j.jpurol.2013.10.011 contributor: fullname: Figueroa – volume: 50 start-page: 1058 year: 2006 ident: 10.1016/j.jpurol.2014.08.009_bib8 article-title: Histologic features in the urinary bladder wall affected from neurogenic overactivity—a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A publication-title: Eur Urol doi: 10.1016/j.eururo.2006.01.025 contributor: fullname: Comperat – volume: 163 start-page: 1228 issue: 4 year: 2000 ident: 10.1016/j.jpurol.2014.08.009_bib9 article-title: Differences in bladder compliance with time and associations of bladder management with compliance in spinal cord injured patients publication-title: J Urol doi: 10.1016/S0022-5347(05)67730-0 contributor: fullname: Weld – volume: 60 start-page: 784 year: 2011 ident: 10.1016/j.jpurol.2014.08.009_bib2 article-title: Contemporary management of lower urinary Tract disease with botulinum toxin a: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA) publication-title: Eur Urol doi: 10.1016/j.eururo.2011.07.001 contributor: fullname: Mangera – volume: 36 start-page: 402 issue: 5 year: 2013 ident: 10.1016/j.jpurol.2014.08.009_bib6 article-title: Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review publication-title: J Spinal Cord Med doi: 10.1179/2045772313Y.0000000116 contributor: fullname: Linsenmeyer – volume: 106 start-page: 1686 issue: 11 year: 2010 ident: 10.1016/j.jpurol.2014.08.009_bib10 article-title: Bladder outlet obstruction: progression from inflammation to fibrosis publication-title: BJU Int doi: 10.1111/j.1464-410X.2010.09445.x contributor: fullname: Metcalfe – volume: 171 start-page: 845 year: 2004 ident: 10.1016/j.jpurol.2014.08.009_bib4 article-title: Botulinum-A injection into the detrusor: a safe alternative in the treatment of children with meningomyelocele with detrusor hyperreflexia publication-title: J Urol doi: 10.1097/01.ju.0000108892.35041.2d contributor: fullname: Riccabona |
SSID | ssj0037029 |
Score | 2.2138972 |
Snippet | Objective Studies on the use of intradetrusor botulinum toxin A injection for children with neuropathic bladders are insufficient and the results are... Studies on the use of intradetrusor botulinum toxin A injection for children with neuropathic bladders are insufficient and the results are controversial. The... OBJECTIVEStudies on the use of intradetrusor botulinum toxin A injection for children with neuropathic bladders are insufficient and the results are... |
SourceID | proquest crossref pubmed elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 27.e1 |
SubjectTerms | Adolescent Botulinum toxin A Botulinum Toxins, Type A - therapeutic use Child Child, Preschool Cholinergic Antagonists - therapeutic use Female Humans Injections, Intramuscular Male Meningomyelocele - complications Neuromuscular Agents - therapeutic use Neuropathic bladder Pediatrics Retrospective Studies Treatment Outcome Urinary Bladder - pathology Urinary Bladder - physiopathology Urinary Bladder, Neurogenic - drug therapy Urinary Bladder, Neurogenic - etiology Urinary Bladder, Neurogenic - physiopathology Urodynamic study Urodynamics Urology |
Title | Botulinum injection is useless on fibrotic neuropathic bladders |
URI | https://www.clinicalkey.es/playcontent/1-s2.0-S1477513114002678 https://dx.doi.org/10.1016/j.jpurol.2014.08.009 https://www.ncbi.nlm.nih.gov/pubmed/25448589 https://search.proquest.com/docview/1667966347 |
Volume | 11 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bS-wwEB50hcN5EW_nuF6WHvC1bmtz65Pooqx6dhEv4Fto0xR20XbZbl_97c70IoqK4GNCQ9pJ8iVf880MwIFAbhwj9Lsx4ykSFJW6iofKZVFgo8imXEhyTh6NxfCeXT7whyUYtL4wJKtssL_G9Aqtm5p-Y83-bDLp3_pMSk7RYhgRCamWYQW3I8Y6sHJycTUct4AcSK9KVkbPu9Sg9aCrZF7TWTnP6Q7CZ1UsT1Imfr5DfXUCrXai8zVYbY6Qzkn9luuwZLMN-DVqLsk34fg0X5C-vHxyJtm0klplzqRwSkqsVBQOllIkyTk2d6pwllVWYuPEj4RC82IL7s_P7gZDt8mT4BqkGwtXJKkximJ5cRak9iiIkHYkeLBIsC6MpUhCJG2hMb5Eq4YijCgOn2KpkjY2SRr8gU6WZ3YbHMYTozyDLIIEfLFUTAmexMqLPOQ9gnXBbW2jZ3U4DN3qxKa6tqUmW2pKbumFXZCtAXXr6ongZItmpRTa18WR9vSH0Xzb8t2E0Ij13_T5rx0pjWuFLkCizOYl9iXor5kImOzC33oIX7-CQrUprsKdH_e7C7-xxGtJ9x50FvPS7uOJZRH3YPnw2e_hvBzc_L_uNfPzBdxI6vI |
link.rule.ids | 315,786,790,4521,24144,27955,27956,45618,45712 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-yDra9lO6zWdvNhb56sWt9-am0oSHbkrw0gbwJW5YhYbVDbL_ub9-dbJeOrQz2aFlC9kk63U_63R3AhUBsnKLq91PGcwQoKvcVj5XPksgmic25kOScPF-I6Yp9W_P1AMa9LwzRKjvd3-p0p627klEnzdFusxndhUxKTtFiGAEJqZ7Bc7IGiNf15ecDzyOSgUtVRrV9qt77zzmS13bX7Eu6gQiZi-RJvMS_709P2Z9uH5ocwWFnQHrX7Te-hoEt3sCLeXdF_haubsqa2OXNvbcpto5oVXibymsorVJVefiUI0Qusbnnglm6nMTGS3-QDtpX72A1uV2Op36XJcE3CDZqX2S5MYoieXEW5fYyShB0ZGhWZFgWp1JkMUK22JhQokxjEScUhU-xXEmbmiyP3sNBURb2GDzGM6MCgxiC6HupVEwJnqUqSAJEPYINwe9lo3dtMAzds8S2upWlJllqSm0ZxEOQvQB17-iJqslW3TqpdKirSx3oP8byccvfpoNGTf-PPs_7kdK4Uuj6Iyls2WBfgs7MRMTkED60Q_jwFxSoTXEVf_zvfj_Dy-lyPtOzr4vvJ_AK3_CW3H0KB_W-sWdou9TpJzc3fwGcHuoy |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Botulinum+injection+is+useless+on+fibrotic+neuropathic+bladders&rft.jtitle=Journal+of+pediatric+urology&rft.au=Tiryaki%2C+S.&rft.au=Yagmur%2C+I.&rft.au=Parlar%2C+Y.&rft.au=Ozel%2C+K.&rft.date=2015-02-01&rft.pub=Elsevier+Ltd&rft.issn=1477-5131&rft.eissn=1873-4898&rft.volume=11&rft.issue=1&rft.spage=27.e1&rft.epage=27.e4&rft_id=info:doi/10.1016%2Fj.jpurol.2014.08.009&rft.externalDocID=S1477513114002678 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14775131%2FS1477513115X00027%2Fcov150h.gif |